An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
Recruiting · Phase 1, Phase 2 · NCT05295433
Conditions: Methylmalonic Acidemia
At a glance
- Research payments reported, 2025
- $423,127
- U.S. investigators named
- 3
- Sites paid
- 4
- Planned or actual enrollment
- 56
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-3705 (drug)
- Dates
- Started 2022-03-08; completion 2034-04-02
- Results posted
- Not yet
The primary objective of this study is to evaluate the long-term safety and clinical activity of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency who have previously participated in other clinical studies of mRNA-3705.
From ClinicalTrials.gov, last updated 2025-12-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $423,127 in research payments for this study in 2025 (33 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Gregory M. Enns, M.D. Medical Genetics · Palo Alto, CA
- Gerald S. Lipshutz, MD Transplant Surgery · Los Angeles, CA
- Can H. Ficicioglu, M.D. Medical Genetics · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Board of Trustees of the Leland Stanford Junior University $239,772
- Ronald Reagan UCLA Medical Center, CA $82,267
- Board of Trustees of the Leland Stanford Junior University $50,707
- Children's Hospital of Philadelphia, PA $50,381
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.